+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID06233461

Evaluating Safety and Effectiveness of Oral TAK-279 for Moderate to Severe Crohns Disease in a Randomized, Double-Blind Study

Led by Takeda · Updated on 2026-11-02

268

Participants Needed

201

Research Sites

22 weeks

Total Duration

AI-Summary

What This Trial Is About

Crohns disease is a long-term condition causing inflammation that can affect any part of the gut. This research aims to evaluate the safety and effectiveness of TAK-279 compared to a placebo in adults with moderately to severely active Crohns disease. The main goal is to find out if three different doses of TAK-279 can reduce bowel inflammation and ulcers after 12 weeks of treatment using endoscopy to assess the bowel. Participants will be randomly assigned to receive one of three doses of TAK-279 or a placebo capsule, taken orally. The treatment period lasts for 52 weeks, or 1 year. The study includes an initial induction phase with treatment assignment and a 4-week safety follow-up phase after completing treatment. The trial is conducted at multiple centers worldwide and involves about 268 participants. Participants will visit the study clinic 15 times during the study. During these visits, researchers will conduct endoscopies and use scores like the Simple Endoscopic Score for Crohns Disease SES-CD and the Crohns Disease Activity Index CDAI to measure inflammation and disease activity. Quality of life and fatigue will also be assessed using questionnaires. Safety and tolerability will be monitored throughout the study and during the follow-up period, with total participation lasting about 60 weeks.

CONDITIONS

Brief Title

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Research Team

T

Takeda Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here